Die Fundamentaldaten des Unternehmens sind relativ stabil. Seine Bewertung wird als unterbewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Das Unternehmen zeigt eine schwache Aktienmarktperformance, die im Einklang mit seinen schwachen Fundamentaldaten und technischen Indikatoren steht. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Zugehörige Informationen
Branchenrang
133 / 207
Gesamtwertung
331 / 4720
Branche
Medizinische Geräte und Verbrauchsmaterialien
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
4
Analysten
Kaufen
Aktuelles Rating
14.400
Kursziel
+966.67%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.